logo

For the Inventor, By the Inventor

Somerset, NJ, United States of America

John G Jurcak

This inventor holds 33 USPTO granted patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Roussel Pharmaceuticals, Aventis Pharmaceuticals Inc., Hoechst Marion Roussel. Active years: 1988-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John G Jurcak. Retrieved from https://idiyas.com/inventor/john-g-jurcak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33

% Patents Active = 69.7


Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 210(Granted Patents)


Location History:

  • Union City, NJ (US) (1992 - 1994)
  • Somerset, NJ (US) (1988 - 1999)
  • Bethlehem, PA (US) (1998 - 2011)

Company Filing History:

goldMedal16 out of 539 
 
Hoechst Roussel Pharmaceuticals
 patents
silverMedal11 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents
bronzeMedal4 out of 236 
 
Hoechst Marion Roussel
 patents
4. 1 out of 1 
 
Frommer Lawrence & Huag LLP
 patent
5. 1 out of 834,513 
Other
 patents

Years Active: 1988-2011

Loading Chart...
Loading Chart...
Areas of Expertise:
Thienopyrazoles
Piperazine Derivatives
Dopamine D3 Receptor Ligands
Antipsychotic Agents
Cyclic Imides
Interleukin-4 Inhibitors
Heterocyclic Amides
Thiazolidinones
Gene Expression Inhibitors
Benzothienylpiperazines
Amino-Pyridonols
Aryl Piperazines
33 patents (USPTO):Explore Patents
1. 7928231 - Thienopyrazoles (2011-04-19),
2. 7777042 - N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof (2010-08-17),
3. 7772252 - [object Object] (2010-08-10),
4. 7550469 - Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands (2009-06-23),
5. 7521445 - [object Object] (2009-04-21),
6. 7518000 - Thienopyrazoles (2009-04-14),
7. 7253165 - [object Object] (2007-08-07),
8. 7186724 - [object Object] (2007-03-06),
9. 7169925 - Indole derivatives as interleukin-4 gene expression inhibitors (2007-01-30),
10. 7091199 - [object Object] (2006-08-15),
11. 6284775 - 3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related compounds (2001-09-04),
12. 5869480 - Substituted-4-amino-3-pyridonols (1999-02-09),
13. 5866565 - Substituted-4-amino-3-pyridinols (1999-02-02),
14. 5821239 - Substituted-4-amino-3-pyridinols (1998-10-13),
15. 5801186 - 3-�4-(1-substituted-4-piperazinyl)butyl!-4-thiazolidinone and related (1998-09-01),

Certainly! Here is the article about inventor John G Jurcak:

Title: Unveiling the Innovations of Inventor John G Jurcak

Introduction: John G Jurcak, a renowned inventor hailing from Somerset, NJ, has left an indelible mark in the world of patents with an impressive total of 33 inventions to his name.

Latest Patents: Among his latest patents are groundbreaking inventions such as 'Thienopyrazoles' and 'N-sulfonylpipecolic acid derivative FKBP binding composition'. These patents encompass innovative formulations and pharmaceutical compositions that target specific disease states through protein kinase inhibition, particularly interleukin-2 inducible tyrosine kinase (ITK).

Career Highlights: John G Jurcak has contributed his expertise to esteemed companies such as Hoechst Roussel Pharmaceuticals and Aventis Pharmaceuticals Inc., where his inventive spirit thrived, leading to the creation of remarkable patented technologies.

Collaborations: Throughout his illustrious career, John G Jurcak has collaborated with esteemed professionals in the field, including coworkers such as Nicholas J Hrib and Gregory Shutske, fostering a collaborative environment that nurtures creativity and propels innovation.

Conclusion: In conclusion, John G Jurcak's prolific portfolio of patents speaks volumes about his dedication to pushing the boundaries of scientific discovery and pharmaceutical advancements. His contributions have not only shaped the industry but have also paved the way for transformative treatments addressing critical medical needs.

Please let me know if you need any further information or assistance.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…